Skip to main content
Fig. 6 | World Journal of Surgical Oncology

Fig. 6

From: Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis

Fig. 6

Validation and prognostic evaluation of MATH value in TP53 and FGFR3 mutation patients in an independent BLCA cohort. a MATH values for TP53-mutant, FGFR3-mutant, and no mutation with TP53 and FGFR3, Kruskal–Wallis test (p > 0.05). b–g Kaplan–Meier survival analysis comparing patients in specific subgroups to all patients in an independent BLCA cohort

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us